Despite notable failures, cancer vaccines are poised for a leap onto the market
October 19, 2017
By Neozene

It’s no secret that cancer vaccines have turned in multiple late-stage failures, putting a serious damper on enthusiasm in the field. But one oncology expert believes we’ll see licensed cancer vaccines in the next two to three years in immuno-oncology combo treatments. Dr. Gerry Messerschmidt, chief medical officer of cancer-focused CRO Precision Oncology, says scientists need to solve several problems inherent to cancer vaccine development. For instance, cancers continuously grow in the body, and they wreak havoc on the immune system. One way to overcome those challenges is by slotting

Read More

Medical Device Cybersecurity Legislation Advances in US Congress
October 17, 2017
By Neozene

New US legislation that would establish a working group led by the Food and Drug Administration to improve cybersecurity measures in medical technology has been introduced in the House of Representatives. The Internet of Medical Things Resilience Partnership Act would task the FDA and other government, academic and industry organizations with developing recommendations and guidelines for boosting cybersecurity and resilience of networked medical devices within 18 months of passage of the Act by the full Congress. The bill appears to take into account recommendations recently published by the Health Care

Read More

Aerie climbs after FDA briefing concurs with efficacy claims
October 12, 2017
By Neozene

Aerie Pharmaceuticals has received good news going into its FDA advisory committee meeting. The FDA agreed with the efficacy conclusion Aerie reached to support its bid for approval of glaucoma and ocular hypertension hopeful Rhopressa. A panel of experts convened by the FDA will take a deep dive into the data and opine on its merits on Friday. The meeting could still throw Aerie a curveball and dent the chances of approval for Rhopressa, which suffered setbacks in the clinic on its way to the FDA filing. But for now

Read More